JSP191

Phase 2Small molecule

JJasper Therapeutics, Inc.

JSP191 is one of 20 small molecule programs targeting Chronic Granulomatous Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Granulomatous DiseaseActive, not recruiting

Fanconi AnemiaRecruiting

Chronic Granulomatous DiseasePhase 1

Active, not recruiting

Fanconi AnemiaPhase 2

Recruiting

Competition

Competitive Landscape

14 competitors in Chronic Granulomatous Disease

#DrugCompanyPhaseTrials

Advil

Busulfex

5 3

Cytoxan

BBaxter Healthcare Corporation

Phase 2

4 4

Rapamune

PPrism Pharmaceuticals

Phase 2

3 5

Campath

GGenzyme, a Sanofi Company

Phase 2

3 6

Tociluzumab

Roche

Phase 2

1 7

Xeljanz

Pfizer

Phase 2

1 8

JSP191

JJasper Therapeutics, Inc.

Phase 2

1 9

Actimmune

HHorizon Therapeutics Ireland DAC

Preclinical

1 10

Emapalumab-Izsg

NNational Institute of Allergy and Infectious Diseases (NIAID)

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1/2Recruiting

Fanconi Anemia

NCT04784052

Q4 2036

Phase 1Active, not recruiting

Chronic Granulomatous Disease

NCT05600907

Clinical

Trials by Indication[1]

MDS1 trial

JSP191 (briquilimab) in Subjects with LR-MDS

Terminated·JJasper Therapeutics, Inc.·Phase 1·NCT05903274·6 enrolled

Fanconi Anemia1 trial

Depleted Donor Stem Cell Transplant in Children and Adults With Fanconi Anemia After Being Conditioned With a Regimen Containing Briquilimab

Recruiting·PPorteus, Matthew, MD·Phase 1/2·NCT04784052·18 enrolled

Chronic Granulomatous Disease1 trial

Pilot Study to Assess the Use of JSP191 in Matched Unrelated Donor Transplantation for Chronic Granulomatous Disease (CGD)

Active, not recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT05600907·7 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for JSP191. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — JSP191 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for JSP191. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jasper Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: JJasper Therapeutics, Inc.

JSP191

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Q4 2036

Trials by Indication[1]

MDS1 trial

Fanconi Anemia1 trial

Chronic Granulomatous Disease1 trial

References

Drug Info

Quick Facts

Related News